Skip to main content

Advertisement

SpringerLink
Log in

Antiobesity drugs: Current and future issues

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Overweight and obesity affect more than 60% of the population in the United States. Many social and environmental factors influence this phenomenon. Because of the tremendous difficulties associated with addressing these factors, health care providers have been looking for a magic pill that resolves this issue. Although there is no panacea, this article is intended to concisely review commonly prescribed medications for obesity, their efficacy, and side effects. In addition, some pharmacologic agents with a promising antiobesity action are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mokdad AH, Bowman BA, Ford ES, et al.: The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286:1195–1200. A very important article that highlights the significance of obesity as an epidemic.

    Article  PubMed  CAS  Google Scholar 

  2. Colditz GA: Economic costs of obesity and inactivity. Med Sci Sports Exerc 1999, 31(suppl 11):S663-S667.

    PubMed  CAS  Google Scholar 

  3. Khan LK, Serdula MK, Bowman BA, Williamson DF: Use of prescription weight loss pills among U.S. adults in 1996–1998. Ann Intern Med 2001, 134:282–286.

    PubMed  CAS  Google Scholar 

  4. Yanovski SZ, Yanovski JA: Drug therapy: obesity. N Engl J Med 2002, 346:591–602.

    Article  PubMed  CAS  Google Scholar 

  5. National Heart, Lung and Blood Institute: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-the Evidence Report. Obesity Res 1998, 6(suppl 2):51S-183S.

    Google Scholar 

  6. Glazer G: Long-term pharmacotherapy of obesity 2000. Arch Intern Med 2001, 161:1814–1824.

    Article  PubMed  CAS  Google Scholar 

  7. Kernan WN, Viscoli CM, Brass LM, et al.: Phenylpropanola-mine and the risk of hemorrhagic stroke. N Engl J Med 2000, 343:1826–1832.

    Article  PubMed  CAS  Google Scholar 

  8. Charatan F: Phenylpropanolamine in drugs could be a risk for stroke. BMJ 2000, 321:1037.

    Article  PubMed  CAS  Google Scholar 

  9. Baumann MH, Ayestas MA, Dersch CM, et al.: Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 2000, 36:102–113.

    Article  PubMed  CAS  Google Scholar 

  10. Rowley HL, Butler SA, Prow MR, et al.: Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse 2000, 38:167–176.

    Article  PubMed  CAS  Google Scholar 

  11. Munro JF, MacCuish AC, Wilson EM, Duncan LJ: Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968, 1:352–354.

    Article  PubMed  CAS  Google Scholar 

  12. Wong J, Reddy SS, Klein AL: Anorectic drugs and valvular heart disease: a biological and clinical perspective. Cleve Clin J Med 1998, 65:35–41.

    PubMed  CAS  Google Scholar 

  13. Connolly HM, Crary JL, McGoon MD, et al.: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581–588.

    Article  PubMed  CAS  Google Scholar 

  14. Connolly HM, McGoon MD: Obesity drugs and the heart. Curr Probl Cardiol 1999, 24:745–792.

    Article  PubMed  CAS  Google Scholar 

  15. Gardin JM, Schumacher D, Constantine G, et al.: Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000, 283:1703–1709.

    Article  PubMed  CAS  Google Scholar 

  16. Jick H, Vasilakis C, Weinrauch LA, et al.: A population-based study of appetite-suppressant drugs and the risk of cardiacvalve regurgitation. N Engl J Med 1998, 339:719–724.

    Article  PubMed  CAS  Google Scholar 

  17. SoRelle R: Fen-Phen and risk of valvular disease. Circulation 1997, 96:1705–1706.

    PubMed  CAS  Google Scholar 

  18. McNeely W, Goa KL: Sibutramine. A review of its contribution to the management of obesity. Drugs 1998, 56:1093–1124.

    Article  PubMed  CAS  Google Scholar 

  19. Finer N, Bloom SR, Frost GS, et al.: Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2000, 2:105–112.

    Article  PubMed  CAS  Google Scholar 

  20. Cuellar GE, Ruiz AM, Monsalve MC, Berber A: Six-month treatment of obesity with sibutramine 15 mg; a doubleblind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000, 8:71–82.

    PubMed  CAS  Google Scholar 

  21. McMahon FG, Fujioka K, Singh BN, et al.: Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebocontrolled, multicenter trial. Arch Intern Med 2000, 160:2185–2191.

    Article  PubMed  CAS  Google Scholar 

  22. Smith IG, Goulder MA: Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001, 50:505–512.

    PubMed  CAS  Google Scholar 

  23. Wirth A, Krause J: Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001, 286:1331–1339. The largest study so far (over 1000 subjects) to look at the efficacy of sibutramine as an antiobesity agent.

    Article  PubMed  CAS  Google Scholar 

  24. Cole JO, Levin A, Beake B, et al.: Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998, 18:231–236.

    Article  PubMed  CAS  Google Scholar 

  25. Schuh LM, Schuster CR, Hopper JA, Mendel CM: Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacologia 2000, 147:339–346.

    Article  CAS  Google Scholar 

  26. Cavaliere H, Floriano I, Medeiros-Neto G: Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001, 25:1095–1099.

    Article  PubMed  CAS  Google Scholar 

  27. Heymsfield SB, Segal KR, Hauptman J, et al.: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000, 160:1321–1326. Extremely important findings with significant impact on the prevalence and development of diabetes.

    Article  PubMed  CAS  Google Scholar 

  28. Hollander PA, Elbein SC, Hirsch IB, et al.: Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288–1294.

    Article  PubMed  CAS  Google Scholar 

  29. Sjostrom L, Rissanen A, Andersen T, et al.: Randomized placebo controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998, 352:167–172. This randomized controlled trial demonstrates the effectiveness of a new class of medicine for treating obesity.

    Article  PubMed  CAS  Google Scholar 

  30. Finer N, James WP, Kopelman PG, et al.: One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000, 24:306–313.

    Article  PubMed  CAS  Google Scholar 

  31. Lindgarde F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000, 248:245–254.

    Article  PubMed  CAS  Google Scholar 

  32. Goldstein DJ, Rampey AH, Dornseif BE, et al.: Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obes Res 1993, 2:92–98.

    Google Scholar 

  33. Goldstein DJ, Rampey AHJr, Enas GG, et al.: Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994, 18:129–135.

    PubMed  CAS  Google Scholar 

  34. Wadden TA, Bartlett SJ, Foster GD, et al.: Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res 1995, 3:549–557.

    PubMed  CAS  Google Scholar 

  35. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP: Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991, 54:321–325.

    PubMed  CAS  Google Scholar 

  36. Dhurandhar NV, Atkinson RL: Comparison of serotonin agonists in combination with phentermine for treatment of obesity. FASEB J 1996, 10:A561.

    Google Scholar 

  37. Liu YL, Toubro S, Astrup A, Stock MJ: Contribution of beta3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord 1995, 19:678–685.

    PubMed  CAS  Google Scholar 

  38. Stock MJ: Potential for beta3-adrenoceptor agonists in the treatment of obesity. Int J Obes Relat Metab Disord 1996, 20(suppl 4):4–5.

    Google Scholar 

  39. Daly PA, Krieger DR, Dulloo AG, et al.: Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993, 17(suppl 1):S73-S78.

    PubMed  Google Scholar 

  40. Toubro S, Astrup AV, Breum L, Quaade F: Safety and efficacy of long-term treatment with ephedrine, caffeine, and an ephedrine/caffeine mixture. Int J Obes Relat Metab Disord 1993, 17(suppl 1):S69-S72.

    PubMed  Google Scholar 

  41. Ascher JA, Cole JO, Colin JN, et al.: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995, 56:395–401.

    PubMed  CAS  Google Scholar 

  42. Harto-Truax N, Stern WC, Miller L, et al.: Effects of bupropion on body weight. J Clin Psychiatry 1983, 44(5 Pt 2):183–186.

    PubMed  CAS  Google Scholar 

  43. Bradley PS, Maddox RR, North WK: Double blind evaluation of bupropion SR(Welbutrin SR) as an adjuvant in drugfacilitated weight reduction-phentermine plus bupropion. Obes Res 1999, 7(suppl 1):92S.

    Google Scholar 

  44. Doose DR, Walker SA, Gisclon LG, Nayak RK: Single dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996, 36:884–891.

    PubMed  CAS  Google Scholar 

  45. Perucca E: A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997, 35:241–256.

    Article  PubMed  CAS  Google Scholar 

  46. Lin MI, Mitchell WG, Chang C, Chen LS: Weight loss due to topiramate [abstract]. Ann Neurol 1999, 46:531.

    Google Scholar 

  47. Appolinario JC, Fontenelle LF, Papelbaum M, et al.: Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry 2002, 47:271–273.

    PubMed  Google Scholar 

  48. Roy Chengappa KN, Levine J, Rathore D, et al.: Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001, 16:186–190.

    Article  PubMed  CAS  Google Scholar 

  49. Picard F, Deshaies Y, Lalonde J, et al.: Topiramate reduces energy and fat gains in lean (Fa/? @#@) and obese (fa/fa) Zucker rats. Obes Res 2000, 8:656–663.

    Article  PubMed  CAS  Google Scholar 

  50. Teter CJ, Early JJ, Gibbs CM: Treatment of affective disorder and obesity with topiramate. Ann Pharmacother 2000, 34:1262–1265.

    Article  PubMed  CAS  Google Scholar 

  51. Shapira NA, Goldsmith TD, McElroy SL: Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000, 61:368–372.

    Article  PubMed  CAS  Google Scholar 

  52. Coleman RA, Herrmann TS: Nutritional regulation of leptin in humans. Diabetologia 1999, 42:639–646.

    Article  PubMed  CAS  Google Scholar 

  53. Herrmann TS, Bean ML, Black TM, et al.: High glycemic index carbohydrate diet alters the diurnal rhythm of leptin but not insulin concentrations. Exp Biol Med 2001, 226:1037–1044.

    CAS  Google Scholar 

  54. Harrold JA, Cai X, Williams G: Leptin, the hypothalamus and the regulation of adiposity. Curr Opin Lipidol 1998, 9:295–299.

    Article  PubMed  CAS  Google Scholar 

  55. Harrold JA, Williams G, Widdowson PS: Early leptin response to a palatable diet predicts dietary obesity in rats: key role of melanocortin-4 receptors in the ventromedial hypothalamic nucleus. J Neurochem 2000, 74:1224–1228.

    Article  PubMed  CAS  Google Scholar 

  56. Halaas JL, Gajiwala KS, Maffei M, et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543–546.

    Article  PubMed  CAS  Google Scholar 

  57. Heymsfield SB, Greenberg AS, Fujioka K, et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282:1568–1575.

    Article  PubMed  CAS  Google Scholar 

  58. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, et al.: Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000, 85:4003–4009.

    Article  PubMed  CAS  Google Scholar 

  59. Kojima M, Hosoda H, Date Y, et al.: Ghrelin is a growth-hormone-releasing acylated peptide from the stomach. Nature 1999, 402:656–660.

    Article  PubMed  CAS  Google Scholar 

  60. Ariyasu H, Takaya K, Tagami T, et al.: The stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001, 86:4753–4758.

    Article  PubMed  CAS  Google Scholar 

  61. Sakata I, Nakamura K, Yamazaki M, et al.: Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 2002, 23:531–536.

    Article  PubMed  CAS  Google Scholar 

  62. Takaya K, Ariyasu H, Kanamoto N, et al.: Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000, 85:4908–4911.

    Article  PubMed  CAS  Google Scholar 

  63. Tschop M, Weyer C, Tataranni PA, et al.: Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50:707–709.

    Article  PubMed  CAS  Google Scholar 

  64. Shiiya T, Nakazato M, Mizuta M, et al.: Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002, 87:240–244.

    Article  PubMed  CAS  Google Scholar 

  65. Hansen TK, Dall R, Hosoda H, et al.: Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol 2002, 56:203–206.

    Article  CAS  Google Scholar 

  66. Cummings DE, Weigle DS, Frayo RS, et al.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002, 346:1623–1630.

    Article  PubMed  Google Scholar 

  67. Wren AM, Small CJ, Ward HL, et al.: The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000, 141:4325–4328.

    Article  PubMed  CAS  Google Scholar 

  68. Wren AM, Seal LJ, Cohen MA, et al.: Ghrelin enhances appetite and increase food intake in humans. J Clin Endocrinol Metab 2001, 86:5992.

    Article  PubMed  CAS  Google Scholar 

  69. Nagaya N, Uematsu M, Kojima M, et al.: Elevated circulating levels of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001, 104:2034–2038.

    PubMed  CAS  Google Scholar 

  70. Nagaya N, Uematsu M, Kojima M, et al.: Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001, 104:1430–1435.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nutrition and Food Science, Wayne State University, 3009 Science Hall, 48202, Detroit, MI, USA

    Nikhil V. Dhurandhar PhD

Authors
  1. M. Ammar Hatahet MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikhil V. Dhurandhar PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hatahet, M.A., Dhurandhar, N.V. Antiobesity drugs: Current and future issues. Curr Diab Rep 2, 409–415 (2002). https://doi.org/10.1007/s11892-002-0105-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-002-0105-3

Keywords

Search

Navigation